Entering text into the input field will update the search result below

Conatus Pharma up after Novartis exercises option

May 04, 2017 8:16 AM ETHistogen Inc. (HSTO) StockBy: Clark Schultz, SA News Editor14 Comments
  • Conatus Pharmaceuticals (CNAT) flies in early trading after the company discloses that Novartis exercised a license for the development and commercialization of Emricasan.
  • The company now believes that it has the financial resources to maintain operations and ongoing clinical development activities through the end of 2019.
  • CNAT +12.95% premarket to $9.16 vs. a 52-week trading range of $1.45 to $9.40.

Recommended For You

About HSTO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
HSTO--
Histogen Inc.